AACR journals editors Robert Kruger and Elizabeth McKenna share how they're working to strengthen ties with the research...
Guest post by Roy S. Herbst, MD, PhD Yale Comprehensive Cancer Center
On Monday, the U.S. Food and Drug Administration (FDA) announced that it had approved the use of the immunotherapeutic...
The flurry of decisions from the U.S. Food and Drug Administration (FDA) on investigational anticancer therapeutics continued last week...
Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the lung cancer community during...
Last week, the U.S. Food and Drug Administration (FDA) approved the use of cobimetinib (Cotellic) in combination with vemurafenib...
The AACR’s disparities conference covered a wide array of issues this year, from the biological factors that make some...
Raymond DuBois, MD, PhD, past-president of the AACR (2008-2009), fellow of the AACR Academy, and chairman and president of...
Guest post by L. Michelle Bennett, director of the NCI Center for Research Strategies; Worta McCaskill-Stevens, MD, chief of...
The flurry of anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) late last month included the...
Kimberly Stegmaier, MD, co-director of the pediatric hematologic malignancy program and associate professor of pediatrics at Dana-Farber Cancer Institute...